Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
UPJ INSIGHT Trends in Prostate-specific Antigen Screening for US Men With a Family History of Prostate Cancer
By: Deepansh Dalela, MD*, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan; Taylor Malchow*, Wright State Boonshoft School of Medicine, Dayton, Ohio; Mohit Butaney, MD, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan; Sami Majdalany, MD, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan; Nicholas J. Corsi, MD, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan, Wayne State University School of Medicine, Detroit, Michigan; Ivan Rakic, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan, Wayne State University School of Medicine, Detroit, Michigan; Akshay Sood, MD, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan; Craig Rogers, MD, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan; Firas Abdollah, MD, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan | Posted on: 19 Sep 2023
* Co-first authors.
Dalela D, Malchow T, Butaney M, et al. Temporal and racial trends in prostate-specific antigen screening for US men with a family history of prostate cancer. Urol Pract. 2023;10(5):484-492.
Study Need and Importance
Guidelines for PSA screening, especially for men with increased risk factors for prostate cancer (PCa) such as a family history of PCa, have been lacking and inconsistent. This study sought to analyze temporal trends in PSA screening for men with a family history of PCa and Black men with a family history of PCa and identify determinants associated with undergoing PSA screening.
What We Found
For men with a family history of PCa, PSA screening increased from 2000 to 2005 with stable rates for the following years (see Figure). Black men with family history of PCa showed no significant change in PSA screening rates during this longitudinal time period. Controlling for sociodemographics and access to health care provider, younger age (40-54) and later survey years (2013-2018) were associated with a lower likelihood of PSA screening overall and for Black men, but not for those with positive family history of PCa.
Limitations
Estimates of PSA screening are subject to recall and nonresponse bias since this study was based on self-reported survey data. Unmeasured confounding variables may have affected PSA screening rates due to the retrospective nature of the study. Misattribution biases could exist due to errors in self-reporting PSA screening. PSA screening recommendations through U.S. Preventive Services Task Force changed at the end of our study period in 2018, and our study only monitored about a half of a year of data after this change.
Interpretation for Patient Care
Our longitudinal study can provide clinicians with a better understanding of PSA screening trends in higher-risk patient populations and the social determinants that correlate with higher and lower screening rates. This comprehensive study that focuses on important PCa risk factors can help guide both provider’s discussions with patients regarding their decision to undergo PSA screening and future recommendations.
advertisement
advertisement